Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 8/20 | 0.67 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.54 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.54 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.53 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.53 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.53 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251697 | 0.95 | DRD2 (0.65) | ATRDRD4DRD2ACVR1 | |
| SCHEMBL3462081 | 0.95 | DRD2 (0.65) | ATRDRD4DRD2ACVR1 | |
| SCHEMBL3461007 | 0.95 | DRD2 (0.65) | ATRDRD4DRD2ACVR1 | |
| SCHEMBL3460396 | 0.88 | HDAC3 (0.58) | ATR | |
| SCHEMBL3460408 | 0.86 | ATR (0.69) | ATRACVR1 | |
| SCHEMBL3460413 | 0.86 | ATR (0.72) | ATRACVR1 | |
| SCHEMBL3460812 | 0.85 | ATR (0.57) | ATRDRD4DRD2ACVR1 | |
| SCHEMBL3460033 | 0.85 | ATR (0.53) | ATRDRD4DRD2 | |
| SCHEMBL3460229 | 0.85 | ATR (0.65) | ATRKMT2A | |
| SCHEMBL3462115 | 0.85 | ATR (0.53) | ATRDRD4DRD2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1501514-A4 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1501514-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | ATR 556/4885DRD4 2855/4885DRD2 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.